{
  "ticker": "SNT",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02970425",
  "id": "02970425",
  "pages": 3,
  "price_sensitive": false,
  "date": "20250718",
  "time": "0828",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250718/pdf/06lx9pf76rh57d.pdf",
  "summary": "- **Clinical Trial Initiation**: Phase 1b/2 AZALOX trial for amsulostat (SNT-5505) in combination with 5-Azacitidine for high-risk Myelodysplastic Neoplasms (MDS) and Chronic Myelomonocytic Leukemia (CMML) commenced at University Medicine Mannheim (first of nine planned centres).  \n- **Trial Funding**: Financially supported by German Cancer Aid (Deutsche Krebshilfe).  \n- **Trial Design**:  \n  - **Phase 1b**: Safety and dosage determination (3-12 patients).  \n  - **Phase 2**: Efficacy evaluation in 30 patients.  \n- **Pipeline Expansion**: Amsulostat is also in development for myelofibrosis (Fast Track Designation granted by FDA).  \n\nNo material trading or capital-raising information identified.",
  "usage": {
    "prompt_tokens": 2298,
    "completion_tokens": 179,
    "total_tokens": 2477,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-17T23:08:22.206342"
}